Drug Information

Drug (ID: DG01044) and It's Reported Resistant Information

• Name: Fosfomycin
• Synonyms: FOSFOMYCIN; phosphomycin; Phosphonomycin; 23155-02-4; Fosfonomycin; Fosfocina; Monurol; Veramina; Fosfomicina; Fosfomycine; Fosfomycinum; [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid; Antibiotic 833A; Phosphonemycin; Phosphonic acid, (3-methyloxiranyl)-, (2R-cis)-; UNII-2N81MY12TE; Phosphomycin disodium salt; (2R-cis)-(3-Methyloxiranyl)phosphonic acid; (1R,2S)-epoxypropylphosphonic acid; L-cis-1,2-epoxypropylphosphonic acid; (-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid; CHEMBL1757; Phosphonicacid, P-[(2R,3S)-3-methyl-2-oxiranyl]-; Fosfomycin disodium salt; 2N81MY12TE; CHEBI:28915; FCM; Phosphonic acid, (1,2-epoxypropyl)-, (1R,2S)-(-)-; (1R,2S)-epoxypropylphosphonate; cis-(1R,2S)-epoxypropylphosphonic acid; Calcium fosfomycin; 1R-cis-(1,2-epoxypropyl)phosphonic acid; ((2R,3S)-3-methyloxiran-2-yl)phosphonic acid; Fosfomicin; Infectophos; 1,2-EPOXYPROPYLPHOSPHONIC ACID; Levo-phosphonomycin; Fosfomycin (USAN/INN); Fosfomycine [INN-French]; Fosfomycinum [INN-Latin]; Fosfomicina [INN-Spanish]; Fosfomycin [USAN:INN:BAN]; J01XX01; EINECS 245-463-1; MK-955; BRN 1680831; 883A; NSC-758170; Fosfomycin (compound 1); Fosfomycinfor culture media; SCHEMBL50951; BIDD:GT0448; BRN 1680831, Fosfocina; ZTI-01; DTXSID4048480; GTPL10813; BCP24891; ZINC1530427; BDBM50024894; cis-(2-Methyloxiranyl)-phosphonic acid; DB00828; (2R,3S)-3-methyloxiran-2-ylphosphonate; 25030-76-6; (1R, 2S)-1,2-epoxypropyl-phosphonic acid; FT-0774116; (2R,3S)-3-methyloxiran-2-ylphosphonic acid; (3-Methyl-oxiranyl)-phosphonic acid(Na salt); C06454; D04253; Q183554; W-107422; BRD-K81101512-234-01-9; Phosphonic acid, P-[(2R,3S)-3-methyl-2-oxiranyl]-; 6F066DFF-696A-4A94-AF78-A28430EBE5BA
• Indication:
  In total 1 Indication(s)
  Bacterial infection [ICD-11: 1A00-1C4Z]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Escherichia coli intestinal infection [ICD-11: 1A03]; [1]
• Target: Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA); MURA_ECOLI; [1]
• Formula: C3H7O4P
• IsoSMILES: C[C@H]1[C@H](O1)P(=O)(O)O
• InChI: 1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1
• InChIKey: YMDXZJFXQJVXBF-STHAYSLISA-N
• PubChem CID: 446987
• ChEBI ID: CHEBI:28915
• TTD Drug ID: D01GYT
• INTEDE ID: DR0749
• DrugBank ID: DB00828

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Escherichia coli intestinal infection [ICD-11: 1A03]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MURA) [1]

• Molecule Alteration: Expression; Inherence
• Resistant Disease: Escherichia coli infection [ICD-11: 1A03.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: THP1 cells; Pleural effusion; Homo sapiens (Human); CVCL_0006
• Mechanism Description: Overexpression of the murA gene by induction of a regulated promoter can lead to greatly increased MICs, to levels that would afford clinical resistance, while having relatively low effects on fitness (relative to mutations to fosfomycin resistance found in clinical isolates).

References

• Ref 1: Fosfomycin: Mechanism and Resistance .Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):a025262. doi: 10.1101/cshperspect.a025262. 10.1101/cshperspect.a025262